Bayer says 2024 sales of prostate cancer drug above $1 bln
21/03/2024 12:00
FRANKFURT, March 21 (Reuters) - Bayer BAYGn.DE on
Thursday predicted at least $1 billion in 2024 sales for
prostate cancer drug Nubeqa, which is playing a bigger role for
the drugmaker's growth prospects after the failure of a
promising anti-blood-clotting therapy.
"Nubeqa ... is set for continued growth in prostate cancer
and is on track to reach blockbuster status this year – only
five years after first indication launch," it said in a
statement.
Blockbuster is an industry term for drugs with at least $1
billion in annual sales.
Bayer chalked up sales of Nubeqa, jointly developed with
Finnish drugmaker Orion ORNBV.HE , of 869 million euros ($948
million) last year and the company has previously projected
annual peak sales potential of more than three billion euros.
Bayer confirmed that even though experimental anticoagulant
asundexian failed last year to sufficiently prevent strokes in
high-risk patients in a trial, another study known as Oceanic
would continue.
Oceanic, to test the drug in patients who have already
suffered a stroke, was "progressing rapidly", it added.
($1 = 0.9162 euros)
(Reporting by Ludwig Burger
Editing by Madeline Chambers)
((ludwig.burger@thomsonreuters.com; +49 30 220133634;))